{
  "document_id": "HOUSE_OVERSIGHT_024666",
  "filename": "IMAGES-008-HOUSE_OVERSIGHT_024666.txt",
  "text": "Cannabis Investment Report |\n\nDecember 2017\n\nRepresentative Dosage Amounts\n\nDesired Effect or Ailment Dosage\n“High” 10 mg THC\nAnxiety, depression, spasms 25 mg CBD\nCancer 25 mg CBD\nChronic pain 2.5-20 mg THC\nEpileptic seizures 200-300 mg CBD\nGlaucoma 20-40 mg CBD\nIncreased appetite 2.5 mg THC\n\nMultiple sclerosis 2.5-120 mg THC\n40-1,280 mg CBD\n\n40-160 mg CBD\n\nSchizophrenia\nSleep disorders\n\nNeither the potential medicinal benefits and therapeutic\n\nDosage Ratio\n(THC:CBD)\n\n10:1 to 100:1\n1:10\n1:1\n10:1\n1:5\n1:2 to 1:4\n5:1\n1:1\n1:4 to 1:128\n1:4 to 1:16\n\napplications of cannabis consumption nor\n\nthe negative side effects of cannabis use have been thoroughly researched by medical science. Short-\n\nterm negative side effects are believed by some to include sensory distortion, panic, anxiety, poor coor-\n\ndination of movement, reduced reaction time, lethargy or drowsiness, depression and elevated heart\n\nrate. Longer-term effects may include suppression of the immune system, growth disorders, destruc-\n\ntion of lung fibers, brain lesions, reduced sexual capacity, difficulties with concentration, reduced abil-\n\nity to learn and retain information, and personality and moo\nabout whether cannabis consumption may lead to the abuse\n“gateway drug” debate).\n\n30\n\nd changes. There is also an ongoing debate\nof more harmful substances (the so-called\n\n© 2017 Ackrell Capital, LLC | Member FINRA/SIPC\n\nHOUSE_OVERSIGHT_024666",
  "metadata": {
    "original_filename": "IMAGES-008-HOUSE_OVERSIGHT_024666.txt",
    "source_dataset": "huggingface:tensonaut/EPSTEIN_FILES_20K",
    "character_count": 1415,
    "word_count": 211,
    "line_count": 63,
    "import_date": "2025-11-19T21:47:45.989238",
    "prefix": "IMAGES-008"
  }
}